Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials

Andrew F Alexis; Paul S Yamauchi; Tina Lin; Gina Martin

doi:10.25251/skin.3.supp.28

Andrew F Alexis

Department of Dermatology, Mount Sinai St Luke?s and Mount Sinai West, New York, NY

Paul S Yamauchi

Dermatology Institute & Skin Care Center, Inc., Santa Monica, CA

Tina Lin

Ortho Dermatologics, Bridgewater, NJ

Gina Martin

Bausch Health Americas, Petaluma, CA

Keywords

psoriasis, tazarotene, halobetasol

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496‑509.

2. Cohen SN, et al. Clin Exp Dermatol. 2012;37 Suppl 1:13‑18.

3. Menter A, et al. J Am Acad Dermatol. 2009;60(4):643‑659.

4. Lam LH, et al. J Drugs Dermatol. 2016; 15(8):945‑948.

5. Sugarman JL, et al. J Drugs Dermatol. 2018;17(8):855‑861.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.28

How to Cite

Alexis, A. F., Yamauchi, P. S., Lin, T., & Martin, G. (2019). Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine, 3, S28. https://doi.org/10.25251/skin.3.supp.28

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Emmy Graber, Hilary Baldwin, Julie C Harper, Linda Stein Gold, Ayman Grada, Andrew F Alexis, Adelaide A Hebert, Richard G Fried, Evan A Rieder, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Leon Kircik, Patient Reported Outcomes (PROs) and Investigator Global assessment (IGA) of Acne Vulgaris among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in real-world community practices across the U.S. (PROSES Study) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Hilary Baldwin, Emmy Graber, Richard G Fried, Evan A Rieder, Julie C Harper, Andrew F Alexis, Linda Stein Gold, Adelaide A Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, Ismail Kasujee, An Expert Panel Questionnaire for Assessing Patient-Reported and Caregiver-Reported Outcomes in Acne Vulgaris , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan I Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis, Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Richard G Fried, Evan A Rieder, Andrew F Alexis, Hilary Baldwin, Emmy Graber, Julie C Harper, Linda Stein Gold, Adelaide A Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Impact of acne on social functioning, emotional functioning, and activities of daily living among patients with moderate to severe non-nodular acne vulgaris administered sarecycline in real-world community practices across the U.S. (PROSES Study) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis, Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Neal Bhatia, Tracey C Vlahovic, Lawrence Green, Gina Martin, Tina Lin, Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Mark G Lebwohl, Lawrence Green, Sylvia Hsu, Shipra Rastogi, Tina Lin, Radhakrishnan Pillai, Robert J Israel, Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Alice Gottlieb, Alan Menter, Paul Yamauchi, George Han, Radhakrishnan Pillai, Tina Lin, Abby Jacobson, Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Julie C Harper, Hilary E Baldwin, Saswata Paul Choudhury, Bikramaditya Ghosh, Deepti Rai, Md Sohail Aman, Abhra Roy Choudhury, Debalina Dey , Sekhar K Dutta, Subrata Bhattacharyya, Tina Lin, George Joseph, Ankur A Dashputre, Jerry Tan, A Systematic Literature Review and Network Meta-Analysis of Comparative Efficacy of Topical Fixed-Dose Combination Treatments for Moderate to Severe Acne Vulgaris , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Zoe Draelos, Fran Cook-Bolden, Lawrence Green, Eric Guenin, Gina Martin, Radhakrishnan Pillai, Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

1 2 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)